This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (462)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Renal Diseases  • Acute Renal Failure  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From the AASK Trial

Jackson T. Wright, Jr, MD, PhD; George Bakris, MD; Tom Greene, PhD; Larry Y. Agodoa, MD; Lawrence J. Appel, MD, MPH; Jeanne Charleston, RN; DeAnna Cheek, MD; Janice G. Douglas-Baltimore, MD; Jennifer Gassman, PhD; Richard Glassock, MD; Lee Hebert, MD; Kenneth Jamerson, MD; Julia Lewis, MD; Robert A. Phillips, MD, PhD; Robert D. Toto, MD; John P. Middleton, MD; Stephen G. Rostand, MD; for the African American Study of Kidney Disease and Hypertension Study Group

JAMA. 2002;288:2421-2431.

Context  Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD.

Objective  To compare the effects of 2 levels of blood pressure (BP) control and 3 antihypertensive drug classes on glomerular filtration rate (GFR) decline in hypertension.

Design  Randomized 3 x 2 factorial trial with enrollment from February 1995 to September 1998.

Setting and Participants  A total of 1094 African Americans aged 18 to 70 years with hypertensive renal disease (GFR, 20-65 mL/min per 1.73 m²) were recruited from 21 clinical centers throughout the United States and followed up for 3 to 6.4 years.

Interventions  Participants were randomly assigned to 1 of 2 mean arterial pressure goals, 102 to 107 mm Hg (usual; n = 554) or 92 mm Hg or less (lower; n = 540), and to initial treatment with either a -blocker (metoprolol 50-200 mg/d; n = 441), an angiotensin-converting enzyme inhibitor (ramipril 2.5-10 mg/d; n = 436) or a dihydropyridine calcium channel blocker, (amlodipine 5-10 mg/d; n = 217). Open-label agents were added to achieve the assigned BP goals.

Main Outcome Measures  Rate of change in GFR (GFR slope); clinical composite outcome of reduction in GFR by 50% or more (or 25 mL/min per 1.73 m²) from baseline, ESRD, or death. Three primary treatment comparisons were specified: lower vs usual BP goal; ramipril vs metoprolol; and amlodipine vs metoprolol.

Results  Achieved BP averaged (SD) 128/78 (12/8) mm Hg in the lower BP group and 141/85 (12/7) mm Hg in the usual BP group. The mean (SE) GFR slope from baseline through 4 years did not differ significantly between the lower BP group (-2.21 [0.17] mL/min per 1.73 m² per year) and the usual BP group (-1.95 [0.17] mL/min per 1.73 m² per year; P = .24), and the lower BP goal did not significantly reduce the rate of the clinical composite outcome (risk reduction for lower BP group = 2%; 95% confidence interval [CI], -22% to 21%; P = .85). None of the drug group comparisons showed consistent significant differences in the GFR slope. However, compared with the metoprolol and amlodipine groups, the ramipril group manifested risk reductions in the clinical composite outcome of 22% (95% CI, 1%-38%; P = .04) and 38% (95% CI, 14%-56%; P = .004), respectively. There was no significant difference in the clinical composite outcome between the amlodipine and metoprolol groups.

Conclusions  No additional benefit of slowing progression of hypertensive nephrosclerosis was observed with the lower BP goal. Angiotensin-converting enzyme inhibitors appear to be more effective than -blockers or dihydropyridine calcium channel blockers in slowing GFR decline.

Author Affiliations: Departments of Medicine, University Hospitals of Cleveland and the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (Dr Wright), Department of Biostatistics, Cleveland Clinic Foundation (Drs Greene and Gassman), and Department of Medicine, Case Western Reserve University (Dr Douglas-Baltimore), Cleveland, Ohio; Department of Preventive Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Dr Bakris); National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Md (Dr Agodoa); Department of Preventive Medicine, Johns Hopkins University, Baltimore, Md (Dr Appel and Ms Charleston); Department of Medicine, Medical University of South Carolina, Charleston (Dr Cheek); Department of Medicine, University of California, Los Angeles (Dr Glassock); Department of Medicine, Ohio State University, Columbus (Dr Hebert); Department of Medicine, University of Michigan, Ann Arbor (Dr Jamerson); Department of Medicine, Vanderbilt University, Nashville, Tenn (Dr Lewis); Mt Sinai School of Medicine, New York, NY (Dr Phillips); University of Texas Southwestern Medical Center, Dallas (Drs Toto and Middleton); and University of Alabama, Birmingham (Dr Rostand).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTERS

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors

JAMA. ;289():2068-2068.
FULL TEXT  

Antihypertensive Drugs and Renal Protection
, , , and
JAMA. ;289():1102-1103.
FULL TEXT  

RELATED ARTICLES

Hypertension Control and Kidney Disease: Some Questions Answered, Many Remain

JAMA. ;288():2466-2467.
FULL TEXT  

Hypertensive Kidney Disease
JAMA. ;288():2498-2498.
 

Long-term Cardiovascular Consequences of Diuretics vs Calcium Channel Blockers vs Angiotensin-Converting Enzyme Inhibitors

JAMA. ;289():2068-2068.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial
Calhoun et al.
Hypertension 2009;54:32-39.
ABSTRACT | FULL TEXT  

The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease
Ku et al.
Arch Intern Med 2009;169:1015-1018.
FULL TEXT  

A role for single-pill triple therapy in hypertension
Elijovich and Laffer
Ther Adv Cardiovasc Dis 2009;3:231-240.
ABSTRACT  

Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?
O'Hare et al.
ANN INTERN MED 2009;150:717-724.
ABSTRACT | FULL TEXT  

The effect of ethnicity on the prevalence of diabetes and associated chronic kidney disease
Dreyer et al.
QJM 2009;102:261-269.
ABSTRACT | FULL TEXT  

Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes
de Galan et al.
J. Am. Soc. Nephrol. 2009;20:883-892.
ABSTRACT | FULL TEXT  

Antihypertensive Prescriptions for Newly Treated Patients Before and After the Main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Results and Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Guidelines
Muntner et al.
Hypertension 2009;53:617-623.
ABSTRACT | FULL TEXT  

Management and control of hypertension and proteinuria in patients with advanced chronic kidney disease under nephrologist care or not: data from the AVENIR study (AVantagE de la Nephroprotection dans l'Insuffisance Renale)
Thilly et al.
Nephrol Dial Transplant 2009;24:934-939.
ABSTRACT | FULL TEXT  

Should nephrologists use beta-blockers? A perspective
Kalaitzidis and Bakris
Nephrol Dial Transplant 2009;24:701-702.
FULL TEXT  

GFR, proteinuria and circadian blood pressure
Agarwal and Light
Nephrol Dial Transplant 2009;0:gfp074v1-gfp074.
ABSTRACT | FULL TEXT  

Disparate Estimates of Hypertension Control From Ambulatory and Clinic Blood Pressure Measurements in Hypertensive Kidney Disease
Pogue et al.
Hypertension 2009;53:20-27.
ABSTRACT | FULL TEXT  

Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials
Turnbull et al.
Eur Heart J 2008;29:2669-2680.
ABSTRACT | FULL TEXT  

Hypertension in Children With Chronic Kidney Disease: A Call to Action
Peralta and Shlipak
Hypertension 2008;52:610-612.
FULL TEXT  

Ethnic Differences in Cardiovascular Drug Response: Potential Contribution of Pharmacogenetics
Johnson
Circulation 2008;118:1383-1393.
FULL TEXT  

Association of a CYP4A11 Variant and Blood Pressure in Black Men
Gainer et al.
J. Am. Soc. Nephrol. 2008;19:1606-1612.
ABSTRACT | FULL TEXT  

High Perfusion Pressure Accelerates Renal Injury in Salt-Sensitive Hypertension
Mori et al.
J. Am. Soc. Nephrol. 2008;19:1472-1482.
ABSTRACT | FULL TEXT  

Renin-Angiotensin System Blockade Is Renoprotective in Immune Complex-Mediated Glomerulonephritis
Guo et al.
J. Am. Soc. Nephrol. 2008;19:1168-1176.
ABSTRACT | FULL TEXT  

Angiotensin-Converting Enzyme Inhibitors and Angioedema: Estimating the Risk
Weber and Messerli
Hypertension 2008;51:1465-1467.
FULL TEXT  

Racial Analysis of Patients With Myocardial Infarction Complicated by Heart Failure and/or Left Ventricular Dysfunction Treated With Valsartan, Captopril, or Both
Prisant et al.
J Am Coll Cardiol 2008;51:1865-1871.
ABSTRACT | FULL TEXT  

Long-term Effects of Renin-Angiotensin System-Blocking Therapy and a Low Blood Pressure Goal on Progression of Hypertensive Chronic Kidney Disease in African Americans
Appel et al.
Arch Intern Med 2008;168:832-839.
ABSTRACT | FULL TEXT  

N-Terminal Prohormone Brain Natriuretic Peptide as a Predictor of Cardiovascular Disease and Mortality in Blacks With Hypertensive Kidney Disease: The African American Study of Kidney Disease and Hypertension (AASK)
Astor et al.
Circulation 2008;117:1685-1692.
ABSTRACT | FULL TEXT  

Management of Cardiovascular Disease in Renal Transplant Recipients
Shirali and Bia
CJASN 2008;3:491-504.
ABSTRACT | FULL TEXT  

Chromogranin A Polymorphisms Are Associated With Hypertensive Renal Disease
Salem et al.
J. Am. Soc. Nephrol. 2008;19:600-614.
ABSTRACT | FULL TEXT  

Cardiovascular Disease in Transplant Recipients: Current and Future Treatment Strategies
Gill
CJASN 2008;3:S29-S37.
ABSTRACT | FULL TEXT  

Prognostic Significance of Between-Arm Blood Pressure Differences
Agarwal et al.
Hypertension 2008;51:657-662.
ABSTRACT | FULL TEXT  

Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes
Richards et al.
Nephrol Dial Transplant 2008;23:549-555.
ABSTRACT | FULL TEXT  

The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design
Knoll et al.
Nephrol Dial Transplant 2008;23:354-358.
ABSTRACT | FULL TEXT  

Slowing Nephropathy Progression: Focus on Proteinuria Reduction
Bakris
CJASN 2008;3:S3-S10.
ABSTRACT | FULL TEXT  

Chronic Kidney Disease after Nonrenal Solid-Organ Transplantation
Bloom and Reese
J. Am. Soc. Nephrol. 2007;18:3031-3041.
ABSTRACT | FULL TEXT  

Prevalence of Chronic Kidney Disease and Survival among Aboriginal People
Gao et al.
J. Am. Soc. Nephrol. 2007;18:2953-2959.
ABSTRACT | FULL TEXT  

Clinical research of kidney diseases II: problems of study design
Ravani et al.
Nephrol Dial Transplant 2007;22:2785-2794.
FULL TEXT  

Race and Ethnicity in Trials of Antihypertensive Therapy to Prevent Cardiovascular Outcomes: A Systematic Review
Park and Taylor
Ann Fam Med 2007;5:444-452.
ABSTRACT | FULL TEXT  

Speaker Abstracts: Tuesday, 6 February 2007
Lamb et al.
Nephrol Dial Transplant 2007;22:ix45-ix53.
FULL TEXT  

REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention
Rosendorff et al.
Hypertension 2007;50:e28-e55.
FULL TEXT  

Blood Pressure Control and Improved Cardiovascular Outcomes in the International Verapamil SR-Trandolapril Study
Mancia et al.
Hypertension 2007;50:299-305.
ABSTRACT | FULL TEXT  

2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Authors/Task Force Members: et al.
Eur Heart J 2007;0:ehm236v1-75.
FULL TEXT  

Development and exploitation of a clinical decision support system for the management of renal anaemia
Will et al.
Nephrol Dial Transplant 2007;22:iv31-iv36.
ABSTRACT | FULL TEXT  

Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention
Rosendorff et al.
Circulation 2007;115:2761-2788.
FULL TEXT  

Albuminuria Is a Target for Renoprotective Therapy Independent from Blood Pressure in Patients with Type 2 Diabetic Nephropathy: Post Hoc Analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Trial
Eijkelkamp et al.
J. Am. Soc. Nephrol. 2007;18:1540-1546.
ABSTRACT | FULL TEXT  

How to tackle the avalanche of chronic kidney disease in sub-Saharan Africa: the situation in the Democratic Republic of Congo as an example
Krzesinski et al.
Nephrol Dial Transplant 2007;22:332-335.
FULL TEXT  

BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval
Bibbins-Domingo and Fernandez
ANN INTERN MED 2007;146:52-56.
ABSTRACT | FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions
Dzau et al.
Circulation 2006;114:2871-2891.
FULL TEXT  

Impact of Blood Pressure Control and Angiotensin-Converting Enzyme Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: A Post Hoc Analysis of the BENEDICT Trial
Ruggenenti et al.
J. Am. Soc. Nephrol. 2006;17:3472-3481.
ABSTRACT | FULL TEXT  

A Primer on the Design, Conduct, and Interpretation of Clinical Trials
Appel
CJASN 2006;1:1360-1367.
ABSTRACT | FULL TEXT  

The Chronic Kidney Disease Epidemic: Stepping Back and Looking Forward
Kiberd
J. Am. Soc. Nephrol. 2006;17:2967-2973.
ABSTRACT | FULL TEXT  

Review: the renoprotective effects of ACE inhibitors and ARBs independent of blood pressure control are uncertain
Clase and Garg
Evid. Based Med. 2006;11:145-145.
FULL TEXT  

Baseline Predictors of Renal Disease Progression in the African American Study of Hypertension and Kidney Disease
Norris et al.
J. Am. Soc. Nephrol. 2006;17:2928-2936.
ABSTRACT | FULL TEXT  

Validation of Creatinine-Based Estimates of GFR When Evaluating Risk Factors in Longitudinal Studies of Kidney Disease
Wang et al.
J. Am. Soc. Nephrol. 2006;17:2900-2909.
ABSTRACT | FULL TEXT  

Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control.
Parikh et al.
Arch Intern Med 2006;166:1884-1891.
ABSTRACT | FULL TEXT  

Progression of Renal Disease: Renoprotective Specificity of Renin-Angiotensin System Blockade
Griffin and Bidani
CJASN 2006;1:1054-1065.
ABSTRACT | FULL TEXT  

Design and Methods of the Chronic Kidney Disease in Children (CKiD) Prospective Cohort Study
Furth et al.
CJASN 2006;1:1006-1015.
ABSTRACT | FULL TEXT  

Clinical Research Methods in CJASN
Hsu and Feldman
CJASN 2006;1:1115-1116.
FULL TEXT  

Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
Leenen et al.
Hypertension 2006;48:374-384.
ABSTRACT | FULL TEXT  

Decline in kidney function before and after nephrology referral and the effect on survival in moderate to advanced chronic kidney disease
Jones et al.
Nephrol Dial Transplant 2006;21:2133-2143.
ABSTRACT | FULL TEXT  

Angiotensin II formation in the kidney and nephrosclerosis in Ren-2 hypertensive rats
Hartner et al.
Nephrol Dial Transplant 2006;21:1778-1785.
ABSTRACT | FULL TEXT  

Surrogate End Points for Clinical Trials of Kidney Disease Progression
Stevens et al.
CJASN 2006;1:874-884.
FULL TEXT  

More Work to Do on Renin-Angiotensin System Blockade
Lit and Meyer
CJASN 2006;1:611-613.
FULL TEXT  

Blood Pressure Reduction Is Not the Only Determinant of Outcome
Sever et al.
Circulation 2006;113:2754-2774.
FULL TEXT  

Re-examining the efficacy of {beta}-blockers for the treatment of hypertension: a meta-analysis
Khan and McAlister
CMAJ 2006;174:1737-1742.
ABSTRACT | FULL TEXT  

Association of Single Measurements of Dipstick Proteinuria, Estimated Glomerular Filtration Rate, and Hematocrit with 25-Year Incidence of End-Stage Renal Disease in the Multiple Risk Factor Intervention Trial
Ishani et al.
J. Am. Soc. Nephrol. 2006;17:1444-1452.
ABSTRACT | FULL TEXT  

Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.
Thornley-Brown et al.
Arch Intern Med 2006;166:797-805.
ABSTRACT | FULL TEXT  

Lessons Learned from Recent Hypertension Trials about Kidney Disease
Khosla and Bakris
CJASN 2006;1:229-235.
FULL TEXT  

CHAPTER 2: Management of Blood Pressure in Hemodialysis Patients
Jindal et al.
J. Am. Soc. Nephrol. 2006;17:S8-S10.
FULL TEXT  

Cardiovascular Outcomes in High-Risk Hypertensive Patients Stratified by Baseline Glomerular Filtration Rate
Rahman et al.
ANN INTERN MED 2006;144:172-180.
ABSTRACT | FULL TEXT  

Changing Relationship of Blood Pressure with Mortality over Time among Hemodialysis Patients
Stidley et al.
J. Am. Soc. Nephrol. 2006;17:513-520.
ABSTRACT | FULL TEXT  

Unexpected Role of TRPC6 Channel in Familial Nephrotic Syndrome: Does It Have Clinical Implications?
Winn et al.
J. Am. Soc. Nephrol. 2006;17:378-387.
FULL TEXT  

Apolipoprotein E and Progression of Chronic Kidney Disease--Reply
Hsu et al.
JAMA 2006;295:35-36.
FULL TEXT  

Opening Words for CJASN
Briggs and Hostetter
CJASN 2006;1:3-5.
FULL TEXT  

Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment
Berl and Henrich
CJASN 2006;1:8-18.
FULL TEXT  

Importance of Race/Ethnicity in Clinical Trials: Lessons From the African-American Heart Failure Trial (A-HeFT), the African-American Study of Kidney Disease and Hypertension (AASK), and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Taylor et al.
Circulation 2005;112:3654-3666.
FULL TEXT  

Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking
Jones-Burton et al.
Nephrol Dial Transplant 2005;20:2739-2745.
ABSTRACT | FULL TEXT  

JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
Prepared by: British Cardiac Society, British Hype
Heart 2005;91:v1-v52.
FULL TEXT  

Differential Effects of {beta}-Blockers on Albuminuria in Patients With Type 2 Diabetes
Bakris et al.
Hypertension 2005;46:1309-1315.
ABSTRACT | FULL TEXT  

Zenon's paradox or how much to lower blood pressure for optimal renoprotection
Wolf
Nephrol Dial Transplant 2005;20:2304-2307.
FULL TEXT  

Intensified blood pressure (BP) control was not better than conventional BP control in non-diabetic chronic renal disease
Culleton
Evid. Based Med. 2005;10:138-138.
FULL TEXT  

Calcium Antagonists: Effects on Cardio-Renal Risk in Hypertensive Patients
Nathan et al.
Hypertension 2005;46:637-642.
ABSTRACT | FULL TEXT  

Target Blood Pressure and Kidney Disease
Kida
ANN INTERN MED 2005;143:310-311.
FULL TEXT  

Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals: The Framingham Heart Study
Arnlov et al.
Circulation 2005;112:969-975.
ABSTRACT | FULL TEXT  

Modest Salt Reduction Reduces Blood Pressure and Urine Protein Excretion in Black Hypertensives: A Randomized Control Trial
Swift et al.
Hypertension 2005;46:308-312.
ABSTRACT | FULL TEXT  

Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli et al.
Circulation 2005;112:171-178.
ABSTRACT | FULL TEXT  

An Editorial Update: What Level of Blood Pressure Control in Chronic Kidney Disease?
Levey and Mulrow
ANN INTERN MED 2005;143:79-81.
FULL TEXT  

Impact of Achieved Blood Pressure on Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial
Berl et al.
J. Am. Soc. Nephrol. 2005;16:2170-2179.
ABSTRACT | FULL TEXT  

Major Clinical Trials of Hypertension: What Should Be Done Next?
The National Heart, Lung, and Blood Institute Work
Hypertension 2005;46:1-6.
ABSTRACT | FULL TEXT  

Blood Pressure Control, Drug Therapy, and Kidney Disease
Contreras et al.
Hypertension 2005;46:44-50.
ABSTRACT | FULL TEXT  

Effects of Different Blood Pressure-Lowering Regimens on Major Cardiovascular Events in Individuals With and Without Diabetes Mellitus: Results of Prospectively Designed Overviews of Randomized Trials
Blood Pressure Lowering Treatment Trialists' Colla
Arch Intern Med 2005;165:1410-1419.
ABSTRACT | FULL TEXT  

Control of Hypertension in Adults With Chronic Kidney Disease in the United States
Peralta et al.
Hypertension 2005;45:1119-1124.
ABSTRACT | FULL TEXT  

Systolic and Diastolic Blood Pressure Lowering as Determinants of Cardiovascular Outcome
Wang et al.
Hypertension 2005;45:907-913.
ABSTRACT | FULL TEXT  

Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Rahman et al.
Arch Intern Med 2005;165:936-946.
ABSTRACT | FULL TEXT  

The Relationship Between Magnitude of Proteinuria Reduction and Risk of End-stage Renal Disease: Results of the African American Study of Kidney Disease and Hypertension
Lea et al.
Arch Intern Med 2005;165:947-953.
ABSTRACT | FULL TEXT  

Outcomes in Hypertensive Black and Nonblack Patients Treated With Chlorthalidone, Amlodipine, and Lisinopril
Wright et al.
JAMA 2005;293:1595-1608.
ABSTRACT | FULL TEXT